Looking to publish in Therapeutic Advances in Hematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowTherapeutic Advances in Hematology is a peer-reviewed open access journal with a strong clinical and pharmacological focus aimed at clinicians and researchers in hematology.
Looking to publish in Therapeutic Advances in Hematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Therapeutic Advances in Hematology accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Review Articles
General Reviews
Perspective Reviews
Drug Reviews
Systematic Reviews
Meta-Analyses
Registered Reports – Pre-Data
Registered Reports – Post-Data
Case Reports
Case Series
Brief Reports
Letters To The Editor
Recent Publications
A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab
Davide Matino, Suchitra S. Acharya, Carrie Turich Taylor, Pengling Sun, Delphine Agathon, Sangeeta Raje, Travis Gould, Andrew Palladino, Johnny Mahlangu
Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?
Miguel A. Escobar, Kaan Kavakli
Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting
Robert Klamroth, Karin Kurnik, Swee Wenning, Carmen Escuriola-Ettingshausen, Stephan Regensburger, Leilei Tang, Joan Gu, Randy Guerra, Johannes Oldenburg
Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
Zahra Mahmoudjafari, Valkal Bhatt, Zhenyi Xue, Franco Locatelli, Gérard Socié, Robert Zeiser
Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study
Priya Patel
Frequently asked questions
How long does it take to publish?
Accepted articles can appear online within an average of 30 days after APC processing.
Reformat to Therapeutic Advances in Hematology using Livewrite PremiumIs a cover letter required?
A cover letter is required. It should explain why the manuscript is suitable for publication and, if fast-track publication is requested, explain why.
Reformat to Therapeutic Advances in Hematology using Livewrite PremiumWhat are the publication costs?
Article processing charges apply for hybrid open access journals. Institutional agreements, prepaid accounts, or affiliation-based discounts may help cover APCs.
Reformat to Therapeutic Advances in Hematology using Livewrite Premium